Next, to test whether either CXCL1 or CXCL2 was necessary for enhancing the anti-tumor effects of HVJ-E, an anti-CXCL1 or CXCL2 antibody was intratumorally injected into melanoma-bearing mice 24 hours before the injection of HVJ-E+poly I:C. The gene discussed is CXCL1; the disease is neoplasm.